On January 8, 2019 Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, reported that in 2018 it entered into agreements with 10 new companies (Press release, Adimab, JAN 8, 2019, View Source [SID1234532584]). In addition, Adimab announced the expansion of seven of its current partnerships and the achievement of 70 technical and development milestones across numerous collaborations.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In the past ten years, Adimab has partnered with over 60 companies for the discovery of therapeutic IgGs and bispecific antibodies, resulting in more than 260 therapeutic programs derived from the Adimab Platform. In 2018, Adimab and its partners added 56 new therapeutic programs. New alliances for 2018 include collaborations with Biotheus, Boehringer Ingelheim, Cullinan Oncology, Cygnal Therapeutics, Pliant Therapeutics, REGiMMUNE, and Werewolf Therapeutics, among others. In addition, Adimab expanded its collaborations with Boehringer Ingelheim, Innovent Biologics, Mapp Biopharmaceutical, Sanofi, Surface Oncology, and Takeda.

"In 2018, we saw fantastic growth in the number of therapeutic programs coming from our platform," said Guy Van Meter, Senior Vice President of Business Development. "In addition to being the leader for antibody discovery, Adimab has become the go-to provider for bispecifics and protein engineering. Our partners really benefit from our deep domain expertise and get to access all our capabilities."

"In an industry that is used to exaggerated claims, we have proven time and time again that we deliver the highest quality therapeutic leads," added Tillman Gerngross, Chief Executive Officer and Co-Founder of Adimab. "To date more than 80% of our partners have expanded their partnership with Adimab, which is a meaningful indicator of the quality of our work."

Over the past five years, Adimab has worked with an increasing number of smaller companies, backed by leading venture capital firms. Following successful antibody discovery campaigns, many of these companies have gone on to partner their programs with larger pharmaceutical companies. Publicly announced transactions include: Tizona and Abbvie (2019), Dragonfly and Merck (2018), Tusk and Roche (2018), Scholar Rock and Gilead (2018), Alector and Abbvie (2017), Dragonfly and Celgene (2017), Mersana and Takeda (2016), Surface Oncology and Novartis (2016), Potenza and Astellas (2015, 2018), and Innovent and Lilly (2015).

"Roche was very thorough in their diligence, and the quality of the leads and the data from Adimab made the process much smoother," said Luc Dochez, former Chief Executive Officer of Tusk Therapeutics.

"Investors and partners invariably conduct extensive diligence on the structural and pharmacological properties of our drug leads," said Arnon Rosenthal, Co-Founder and Chief Executive Officer of Alector. "Adimab data and the support of the Adimab team were critical elements in developing compelling product candidates."

"Adimab has been a fantastic partner. The Adimab team is comprised of leading scientists, using state of the art technology, who have a sense of urgency towards their collaborators. I cannot praise them highly enough," said Bill Haney, Co-Founder and Chief Executive Officer of Dragonfly Therapeutics.